{"member_organisations": "", "identification_number": "322536115782-29", "fields_of_interest": "General and Institutional Affairs, Trade, Competition, Business and Industry, Taxation, Single market, Research and innovation, Public Health", "head_office_address": "1st Ave, 1020", "full_time_equivalent_fte": "1,25", "person_with_legal_responsibility": "Gregory Boss", "industry_forums": "", "grants": "", "country_code": "us", "inter_groups": "", "eu_initiatives": "CSL Behring participates in policy discussions with the EU institutions and European stakeholders that are pertinent to biopharmaceutical sector. Our foremost priority is to improve access to care for patients with rare and serious diseases. We are particularly interested in the legislative developments in the areas of pharmaceuticals, healthcare, innovation and research, internal market, trade, and business competitiveness.", "level_of_interest": "global", "organisation_name": "CSL Behring", "belgium_office_post_code": "", "number_of_persons_involved": "3", "person_in_charge_of_eu_relations": "Ruediger Gatermann", "section": "II - In-house lobbyists and trade/business/professional associations", "lon": "-75.4100737847588", "source": "", "subsection": "Companies & groups", "belgium_office_phone": "(+32)15288923", "overall_budget_turnover_as_a_range": "", "belgium_office_address": "Bedrijvenlaan 11", "persons_accredited_for_access_to_european_parliament_premises": "GATERMANN#Ruediger, Khraiche#Joelle", "registration_date": "02/02/2015", "estimate_of_costs_absolute_amount": "", "website_address": "http://www.cslbehring.com/", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "King of Prussia", "membership": "Plasma Protein Therapeutic Association (PPTA) \nThe European Association of Bio-Industries (EuropaBio) \nEuropean Confederation of Pharmaceutical Entrepreneurs (EUCOPE)", "head_office_post_code": "PA 19406", "position": "Director Healthcare Policy & External Affairs", "financial_year_start_date": "01/07/2016", "head_office_country": "United States", "number_of_ep_accredited_persons": "2", "relevant_communication": "", "financial_year_end_date": "01/06/2017", "lat": "40.095188210537", "estimate_of_costs_as_a_range": "50000-99999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Corporate", "procurement": "", "customers": "", "belgium_office_post_box": "", "goals__remit": "The CSL Behring story spans decades of innovation, collaboration, patient focus, and an ongoing drive for excellence. CSL Behring is a global leader in the therapeutic protein industry. Committed to saving and improving the lives of people with rare and serious medical disorders, we research, develop, manufacture and market plasma-derived and recombinant biotherapies. \n \nOur biotherapies replace components missing in the blood of patients and are used around the world to treat coagulation disorders such as hemophilia and von Willebrand disease (VWD), primary immune deficiencies, hereditary angioedema and inherited respiratory disease, as well as neurological disorders in certain markets. We also manufacture products used in cardiac surgery, organ transplantation, and burn treatment, and to treat acquired bleeding, reverse the effects of warfarin, and prevent hemolytic disease of the newborn. Patients come first in all we do. \n \nOur products are produced at facilities in Bern, Switzerland; Marburg, Germany; Kankakee, Illinois and Broadmeadows, Australia, in accordance with international safety and quality standards. The company employs more than 14,000 people in 30 countries. CSL Behring is a subsidiary of CSL Limited.", "belgium_office_city": "Mechelen", "head_office_phone": "(+1)6108784000"}